Scott Marsh Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

Scott Marsh Financial’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$670K	Buy	+1,504	New	+$693K	0.25%	126

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Scott Marsh Financial's VRTX Position: Q2 2025 in Review

Scott Marsh Financial opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2025: 1,504 shares worth $670K. The stake represents 0.25% of the portfolio and ranks #126 among its holdings.

1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

Scott Marsh Financial held 1,504 shares of Vertex Pharmaceuticals worth $670K as of Q2 2025.
Vertex Pharmaceuticals was a new Scott Marsh Financial position in Q2 2025.
Vertex Pharmaceuticals made up 0.25% of Scott Marsh Financial's portfolio in Q2 2025, its #126 holding.
1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Scott Marsh Financial's 13F filing for Q2 2025, filed 14 Aug 2025.